Table 4 Univariate and multivariate Cox regression analysis of TP53 gene mutation combined with clinicopathologic features
From: Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
| Â | HR (95% CI) | P value |
|---|---|---|
Univariates | ||
 TP53-exp | 0.921 (0.762–1.11) | 0.392 |
 Group-WT | 0.745 (0.556–0.998) | 0.0484 |
 Gender | 1.05 (0.78–1.4) | 0.765 |
 Age | 1.01 (0.994–1.02) | 0.24 |
 Eastern cancer oncology group | 1.72 (1.25–2.35) | 0.000742 |
Person neoplasm cancer status | ||
 TUMOR FREE | 0.165 (0.104–0.259) | 4.81E−20 |
 WITH TUMOR | 1.33 (0.963–1.84) | 4.81E−20 |
New tumor event after initial treatment | ||
 NO | 0.274 (0.185–0.407) | 5.89E−13 |
 YES | 0.966 (0.681–1.37) | 5.89E−13 |
Radiation therapy | ||
 NO | 0.375 (0.265–0.531) | 1.11E−08 |
 YES | 0.825 (0.524–1.3) | 1.11E−08 |
Additional pharmaceutical therapy | ||
 NO | 2.71 (1.9–3.85) | 1.30E−07 |
 YES | 1.68 (1.13–2.48) | 1.30E−07 |
Additional radiation therapy | ||
 NO | 2.1 (1.47–3.01) | 7.82E−06 |
 YES | 2.05 (1.39–3.01) | 7.82E−06 |
Additional surgery locoregional procedure | ||
 NO | 2.29 (1.68–3.14) | 1.13E−06 |
 YES | 0.986 (0.363–2.67) | 1.13E−06 |
Additional surgery metastatic procedure | ||
 NO | 2.36 (1.69–3.28) | 1.85E−06 |
 YES | 1.65 (0.887–3.06) | 1.85E−06 |
Primary therapy outcome success | ||
 Complete Remission/Response | 0.297 (0.21–0.421) | 1.12E−15 |
 Partial Remission/Response | 0.493 (0.0683–3.55) | 1.12E−15 |
 Progressive Disease | 1.5 (1.02–2.21) | 1.12E−15 |
 Stable Disease | 0.482 (0.241–0.965) | 1.12E−15 |
Pathologic-T | ||
 T1a | 1.59 (0.768–3.27) | 0.000469 |
 T1b | 1.08 (0.496–2.36) | 0.000469 |
 T2 | 1.72 (1.09–2.71) | 0.000469 |
 T2a | 1.31 (0.679–2.54) | 0.000469 |
 T2b | 1.08 (0.411–2.86) | 0.000469 |
 T3 | 3.41 (1.88–6.18) | 0.000469 |
 T4 | 3.24 (1.58–6.64) | 0.000469 |
 TX | 5.18 (1.21–22.2) | 0.000469 |
Tumor stage | ||
 Stage | 0.787 (0.0712–8.69) | 6.43E−09 |
 Stage IA | 0.908 (0.216–3.82) | 6.43E−09 |
 Stage IB | 0.979 (0.235–4.09) | 6.43E−09 |
 Stage IIA | 2.67 (0.62–11.5) | 6.43E−09 |
 Stage IIB | 2.03 (0.483–8.52) | 6.43E−09 |
 Stage IIIA | 3.5 (0.838–14.6) | 6.43E−09 |
 Stage IIIB | 2.4 (0.484–11.9) | 6.43E−09 |
 Stage IV | 3.61 (0.824–15.8) | 6.43E−09 |
Multivariates | ||
 Group-WT | 0.72 (0.53–0.98) | 0.035 |
Additional pharmaceutical therapy | ||
 NO | 2.3 (0.99–5.2) | 0.052 |
 YES | 1 (0.44–2.4) | 0.96 |
New tumor event after initial treatment | ||
 NO | 0.29 (0.19–0.44) | 1.20E−08 |
 YES | 0.67 (0.29–1.5) | 0.35 |
Pathologic T | ||
 T1a | 3.4 (1.6–7.4) | 0.0016 |
 T1b | 1.5 (0.66–3.4) | 0.33 |
 T2 | 1.7 (0.9–3.2) | 0.099 |
 T2a | 1.6 (0.73–3.3) | 0.25 |
 T2b | 0.67 (0.24–1.9) | 0.45 |
 T3 | 2 (0.94–4.4) | 0.072 |
 T4 | 3.5 (1.2–9.9) | 0.019 |
 TX | 5.6 (1.1–29) | 0.039 |
Tumor stage | ||
 Stage I | 1 (0.092–12) | 0.97 |
 Stage IA | 0.8 (0.18–3.6) | 0.77 |
 Stage IB | 0.78 (0.18–3.4) | 0.75 |
 Stage II | 4.8 (0.39–59) | 0.22 |
 Stage IIA | 3 (0.65–14) | 0.16 |
 Stage IIB | 1.5 (0.34–6.4) | 0.61 |
 Stage IIIA | 2.8 (0.66–12) | 0.17 |
 Stage IIIB | 0.66 (0.11–4.1) | 0.66 |
 Stage IV | 1.8 (0.39–8.3) | 0.45 |